New Three-Drug cocktail shows promise for Hard-to-Treat myeloma
NCT ID NCT07348393
First seen Jan 17, 2026 · Last updated May 08, 2026 · Updated 17 times
Summary
This study tests a new combination of three drugs (mezigdomide, carfilzomib, and dexamethasone) in about 70 adults whose multiple myeloma has returned or stopped responding to prior treatments, including lenalidomide and anti-CD38 therapy. The goal is to see if this combination can delay cancer progression and improve survival. Participants must have tried at least one prior therapy but never received carfilzomib.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Saint-Antoine Hospital
Paris, 75012, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.